[ FDA CIRCULAR NO. 2013-022, August 23, 2013 ]
GUIDELINES ON HANDLING CONSUMER COMPLAINTS
In order to carry out this duty to uphold consumer rights and to strengthen the promotion of consumer welfare, there is a need to streamline the procedures in handling consumer complaints for all the offices of the Food and Drug Administration. Notwithstanding, it must be emphasized that the best interest of the consumer shall be considered in the interpretation and implementation of the provisions of this Circular.
Consumer empowerment does not only mean providing wide choices of consumer products and services but also the establishment of mechanism to effectively address concerns and issues arising from the quality and standards of products and services.
It is for this purpose that the following guidelines for handling consumer complaints are laid down for the information of the public:
II. Scope:
These guidelines shall apply to consumer complaints filed before the FDA for health products and services including advertisements and sales promotions under its jurisdiction not otherwise taken cognizance by the Consumer Arbitrators under Sec. 163 of RA 7394 or other tribunals, quasi-judicial bodies and the regular courts.
III. Guidelines:
Section 1. General Guidelines
1.1 |
Complainant shall proceed to the concerned FDA Center/Office to file a consumer complaint. |
|
1.1.1 |
Processed Food Products, & Food Supplements - Center for Food Regulation and Research (CFRR) |
|
1.1.2 |
Cosmetics, Household/Urban Hazardous Substance and Pesticides - Center for Cosmetic Regulation and Research (CCRR) |
|
1.1.3 |
Drug, Herbal, Traditional, Veterinary Drug
Products, Vaccine and Biological Products - Center for Drug Regulation
and Research (CDRR) |
|
1.1.4 |
Medical Devices, among others - Center for Device Regulation, Radiation Health and Research (CDRRHR) |
|
1.2 |
The complainant shall
accomplish the Complaint Form (Annex A - downloadable thru FDA
Website) for walk-in complainants and e-mail complaints. For complaints
received through the phone, the concerned FDA Center/Office personnel
shall accomplish the complaint form. |
|
1.3 |
For phone-in complaints, the
concerned FDA Center/Office personnel shall properly fill out the
details needed and certify that the information set forth in the
complaint form faithfully reflects the statements made by the
complainant. |
|
1.4 |
FDA Center/Office
representative shall conduct a thorough interview on the matter of the
complaint to determine the next appropriate action needed. Information
on the complaint must be based on the complainant's personal knowledge
and experience. The complainant shall affix his/her signature on the
form CONFORME: (Complainant). |
|
1.5 |
The complainant shall attach or
submit the necessary supporting documents or piece/s of evidence, such
as but not limited to the following: photographs, materials, receipts,
medical certificate, and product subject of complaint. |
|
1.6 |
Complaint product requiring
laboratory analysis shall be referred to the Laboratory only after
evaluation of Center personnel that the complaint product meets the
criteria for acceptance set forth in this guideline. The FDA
Center/Office personnel shall accomplish the Laboratory Analysis
Referral Form (Annex B ) and shall be acknowledged and signed by the
Laboratory personnel. |
|
1.7 |
The complainant shall be advised of the action that will be taken. |
Section 2. Specific Guidelines
2.1 |
For health products referred
for laboratory analysis, the following criteria shall be observed for
opened and unopened products submitted for physico/chemical test: |
||
2.2.1 | Criteria for Acceptance: | ||
A. | Food Product
|
||
B. | Drug Product
|
||
C. | Cosmetics and Household/Urban Hazardous Substances
|
||
2.1.2 | Criteria for rejection for Microbiological Analysis (Food, Drug and Cosmetic Products)
|
Section 3. Types of Consumer Complaints that the FDA Does Not Handle
3.1 |
Restaurant/fast food/hotel/hospital/airline/shipping lines/home-cooked prepared foods and beverages; |
3.2 |
Street foods such as betamax , adidas , IUD or isaw, baticolon , kwek kwek , taho, and the like; |
3.3 |
Tingi-tingi or takal-takal food products sold in public markets/sari-sari stores; |
3.4 |
Fresh produce (fruits, vegetables, root crops, poultry, cow s milk, carabao s milk, seafood, meat products; |
3.5 |
Water from refilling station, and tap water except bottled water; |
3.6 |
Rice grains and other grains; |
3.7 |
Products suspected in accidental/Intentional poisoning; |
3.8 |
Dangerous drugs, as defined by law; |
3.9 |
Agricultural pesticides and fertilizers; |
3.10 |
Products used in medical malpractice; |
3.11 |
Products subject to senior citizen discount; |
3.12 |
Products involved in violation of Price
Act, except for drug products covered by the Maximum Drug Retail Price
(MDRP) and Government Mediated Access Price (GMAP); |
3.13 |
Products subject of complaint on trade of a
company against another company, except on cases involving health
product being counterfeited; and |
3.14 |
All processed canned and meat products. |
Section 4. Additional Guidelines
The public is reminded to be vigilant in buying processed food, drugs, cosmetics and other health products to ensure their safety. Consumers are encouraged to observe the following recommendations:
4.1 |
Buy health products from licensed and legitimate establishments. |
4.2 |
Be vigilant and buy only registered health products. |
4.3 |
Do not buy products with foreign labels or without English or Filipino translations. |
4.4 |
Always check the label for the expiry date or best before date. |
4.5 |
Avoid buying health product with dented or deformed packaging. |
4.6 |
Check www.fda.gov.ph web site for verification of registered health products. |
4.7 |
You may also report on-line at www.fda.gov.ph: tab eReport or please email directly at report@fda.gov.ph. |
4.8 |
For complaints involving Adverse Drug Reaction (ADR), please accomplish on-line ADR Form at www.fda.gov.ph: tab ADR Report . |
4.9 |
For more information and clarification, please email info@fda.gov.ph. |
This Circular shall take effect immediately.
(SGD) KENNETH Y. HARTIGAN-GO, MD
Acting Director General